News Article | February 23, 2017
A brain-to-computer hookup recently allowed people with severe limb weakness to type via direct brain control at the highest speeds and accuracy levels reported to date. Two of the participants have amyotrophic lateral sclerosis, also called Lou Gehrig’s disease, and one has a spinal cord injury. They each had one or two baby-aspirin-sized electrode arrays placed in their brains to record signals from the motor cortex, a region controlling muscle movement. The signals were transmitted to a computer via a cable and translated by algorithms into point-and-click commands guiding a cursor to characters on an onscreen keyboard. Each participant, after minimal training, mastered the technique sufficiently to outperform the results of any previous test of brain-computer interfaces, or BCIs, for enhancing communication by people with similarly impaired movement. Notably, they achieved the typing rates without the use of automatic word-completion assistance common in electronic keyboarding applications nowadays, which likely would have boosted their performance. One participant, Dennis Degray of Menlo Park, California, was able to type 39 correct characters per minute, equivalent to about eight words per minute. This point-and-click approach could be applied to a variety of computing devices, including smartphones and tablets, without substantial modifications, the researchers say. Their findings appear in the journal eLife. “Our study’s success marks a major milestone on the road to improving quality of life for people with paralysis,” says Jaimie Henderson, professor of neurosurgery at Stanford University, who performed two of the three device-implantation procedures at Stanford Hospital. The third took place at Massachusetts General Hospital. “This study reports the highest speed and accuracy, by a factor of three, over what’s been shown before,” says co-senior author Krishna Shenoy, professor of electrical engineering. “We’re approaching the speed at which you can type text on your cellphone.” “The performance is really exciting,” says former postdoctoral scholar Chethan Pandarinath, who now has a joint appointment at Emory University and the Georgia Institute of Technology as an assistant professor of biomedical engineering. “We’re achieving communication rates that many people with arm and hand paralysis would find useful. That’s a critical step for making devices that could be suitable for real-world use.” Shenoy’s lab pioneered the algorithms used to decode the complex volleys of electrical signals fired by nerve cells in the motor cortex, the brain’s command center for movement, and convert them in real time into actions ordinarily executed by spinal cord and muscles. “These high-performing BCI algorithms’ use in human clinical trials demonstrates the potential for this class of technology to restore communication to people with paralysis,” says postdoctoral scholar Paul Nuyujukian. Millions of people with paralysis live in the United States. Sometimes their paralysis comes gradually, as occurs in ALS. Sometimes it arrives suddenly, as in Degray’s case. Now 64, Degray became quadriplegic on October 10, 2007, when he fell and sustained a life-changing spinal-cord injury. “I was taking out the trash in the rain,” he said. Holding the garbage in one hand and the recycling in the other, he slipped on the grass and landed on his chin. The impact spared his brain but severely injured his spine, cutting off all communication between his brain and musculature from the head down. “I’ve got nothing going on below the collarbones,” he says. Degray received two device implants at Henderson’s hands in August 2016. In several ensuing research sessions, he and the other two study participants, who underwent similar surgeries, were encouraged to attempt or visualize patterns of desired arm, hand, and finger movements. Resulting neural signals from the motor cortex were electronically extracted by the embedded recording devices, transmitted to a computer and translated by Shenoy’s algorithms into commands directing a cursor on an onscreen keyboard to participant-specified characters. The researchers gauged the speeds at which the patients were able to correctly copy phrases and sentences—for example, “The quick brown fox jumped over the lazy dog.” Average rates were 7.8 words per minute for Degray and 6.3 and 2.7 words per minute, respectively, for the other two participants. The investigational system used in the study, an intracortical brain-computer interface called the BrainGate Neural Interface System, represents the newest generation of BCIs. Previous generations picked up signals first via electrical leads placed on the scalp, then by being surgically positioned at the brain’s surface beneath the skull. An intracortical BCI uses a tiny silicon chip, just over one-sixth of an inch square, from which protrude 100 electrodes that penetrate the brain to about the thickness of a quarter and tap into the electrical activity of individual nerve cells in the motor cortex. Henderson likened the resulting improved resolution of neural sensing, compared with that of older-generation BCIs, to that of handing out applause meters to individual members of a studio audience rather than just stationing them on the ceiling, “so you can tell just how hard and how fast each person in the audience is clapping.” The day will come—closer to five than 10 years from now, Shenoy predicts—when a self-calibrating, fully implanted wireless system can be used without caregiver assistance, has no cosmetic impact. and can be used around the clock. “I don’t see any insurmountable challenges,” he says. “We know the steps we have to take to get there.” Degray, who continues to participate actively in the research, knew how to type before his accident but was no expert at it. He described his newly revealed prowess in the language of a video game aficionado. “This is like one of the coolest video games I’ve ever gotten to play with,” he says. “And I don’t even have to put a quarter in it.” Stanford research assistant Christine Blabe is also a study coauthor, as are BrainGate researchers from Massachusetts General Hospital and Case Western University. Funding came from the National Institutes of Health, the Stanford Office of Postdoctoral Affairs, the Craig H. Neilsen Foundation, the Stanford Medical Scientist Training Program, Stanford BioX-NeuroVentures, the Stanford Institute for Neuro-Innovation and Translational Neuroscience, the Stanford Neuroscience Institute, Larry and Pamela Garlick, Samuel and Betsy Reeves, the Howard Hughes Medical Institute, the US Department of Veterans Affairs, the MGH-Dean Institute for Integrated Research on Atrial Fibrillation and Stroke, and Massachusetts General Hospital. Stanford’s Office of Technology Licensing holds intellectual property on the intercortical BCI-related engineering advances made in Shenoy’s lab.
News Article | February 28, 2017
In study, children with a particular genetic variation were 4 times more likely to develop strong attachment to mother after intervention Toronto, Canada / Cape Town, South Africa - A child's genetic make-up can play a large, hidden role in the success of efforts to maximize his or her development, South African research suggests. The study, published February 28 in PLoS Medicine and supported by the Government of Canada through Grand Challenges Canada's Saving Brains program, sheds new light on why some children benefit more than others from interventions and raises complex questions about psychosocial intervention programs in future. In a study led by Professor Mark Tomlinson of Stellenbosch University, the study followed-up an intervention implemented between 1999 and 2003, in which expectant mothers underwent mentoring to improve attachment with their children -- attachment being a measure of a child's psychological security, and predictive of future wellbeing. In the original study, a control group of roughly equal size was composed of expectant mothers who did not receive mentoring. The original study concluded that the intervention had a small-to-moderate effect on mother-child attachment, evaluated once the children reached 18 months of age. The follow-up study, conducted thirteen years after the intervention, re-examined the original attachment results and revealed something surprising: the intervention had in fact worked well for toddlers who had a particular genetic characteristic. Conducted in collaboration with colleagues from the University of Reading, University College London, and Western University, the study re-enrolled and conducted genetic tests on 279 of the original 449 children. 220 children had both genetic and attachment data, enabling the investigators to test whether the original attachment outcomes were influenced by their genes. The researchers factored in whether the child had the short or long form of gene SLC6A4 -- the serotonin transporter gene, which is involved in nerve signalling, and which other studies have linked to anxiety, depression and other conditions. Serotonin is popularly thought to contribute to feelings of well-being and happiness. The attachment of children with the short form of the gene, and whose pregnant mothers were mentored, were almost four times more likely to be securely attached to their mothers at 18 months old (84 percent were secure) than children carrying the short form whose mothers did not receive mentoring (58 percent were secure). Meanwhile, children with the long gene were apparently unaffected by their mother's training or lack thereof: in both cases, the rate of secure attachment was almost identical (70 and 71 percent). Subject to further validation, says Professor Tomlinson, the insight has "important implications for scientists designing and evaluating interventions to benefit as many people as possible in South Africa and worldwide." "Without taking genetics into account, it is possible that other studies have under-estimated the impact of their interventions, as we originally did." Says lead author Dr. Barak Morgan of the University of Cape Town: "The immediate significance of this research is the revelation that in principle, and probably in many cases in practice too, the effectiveness of interventions has been mis-measured -- under-estimated for genetically susceptible individuals and over-estimated for those who are genetically less susceptible. But even more worrying is the implication that the negative consequences of not receiving an intervention also differ by genotype." "This is an enormously important insight because, in this case, the subgroup with the short form of the SLC6A4 gene is also the one with the most to lose if not helped." "Individuals with the long form of the gene, on the other hand, appear less sensitive and derived little benefit from the same intervention, and little detriment from not getting it." Adds Professor Tomlinson: "In the original study, we did not see such a big impact from this intervention because only those with the short gene improved, and this improvement was 'diluted' by the large number of children with the long gene who did not improve." The researchers caution that, among other limitations, this study involved a relatively small sample and only measured one gene and one outcome (attachment). Dr. Morgan stressed: "We are certainly not saying that only some people should receive the intervention -- those who are 'susceptible' to improving from it. There is little scientific justification for this. For example, many children with the non-susceptible long genotype of the SLC6A4 gene may carry the susceptible form of another gene which renders them much more likely to benefit from the same intervention but for a different but equally important outcome. "Going forward, the implications are therefore two-fold. Firstly, measuring genetic differences allows for proper assessment of the effectiveness or lack of effectiveness of an intervention for a particular outcome in different individuals. Secondly, this information can then be used to find out how to intervene effectively for all -- to guide what might be done to improve outcomes for a non-responsive gene-intervention interaction while continuing to optimise outcomes for the responsive one." Says Dr. Karlee Silver, Vice President Programs of Grand Challenges Canada: "This work is fundamentally about better understanding the impact of interventions which is an important step forward to creating a world where every child can survive and thrive." Says Dr. Peter A. Singer, Chief Executive Officer of Grand Challenges Canada: "This is a startling finding that changes the way I think about child development. Why is it important? Because child development is the ladder of social mobility used to climb out of the hole of inequity by millions of children around the world." For more information, visit grandchallenges.ca and look for us on Facebook, Twitter, YouTube and LinkedIn. Grand Challenges Canada is dedicated to supporting Bold Ideas with Big Impact® in global health. We are funded by the Government of Canada and we support innovators in low- and middle-income countries and Canada. The bold ideas we support integrate science and technology, social and business innovation - we call this Integrated Innovation®. Grand Challenges Canada focuses on innovator-defined challenges through its Stars in Global Health program and on targeted challenges in its Saving Lives at Birth, Saving Brains and Global Mental Health programs. Grand Challenges Canada works closely with Canada's International Development Research Centre (IDRC), the Canadian Institutes of Health Research (CIHR) and Global Affairs Canada to catalyze scale, sustainability and impact. We have a determined focus on results, and on saving and improving lives. http://www. Saving Brains is a partnership of Grand Challenges Canada, Aga Khan Foundation Canada, the Bernard van Leer Foundation, the Bill & Melinda Gates Foundation, The ELMA Foundation, Grand Challenges Ethiopia, the Maria Cecilia Souto Vidigal Foundation, the Palix Foundation, UBS Optimus Foundation and World Vision Canada. It seeks and supports bold ideas for products, services and implementation models that protect and nurture early brain development relevant to poor, marginalized populations in low- or middle-income countries. http://www.
News Article | February 15, 2017
TORONTO, ONTARIO--(Marketwired - Feb. 8, 2017) - Newstrike Resources Ltd. (TSX VENTURE:NR) ("Newstrike" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") with HPI Holdings Ltd. ("HPI") pursuant to which Newstrike and HPI will effect a business combination (the "Transaction"). The Agreement was negotiated at arm's length and is effective as of February 3, 2017. HPI is a company governed by the laws of Ontario and, through its wholly-owned subsidiary 8455562 Canada Inc., is engaged in the production of medical marijuana in Brantford, Ontario. On December 19, 2016, HPI obtained its production license from Health Canada. As of December 31, 2016, preliminary numbers, subject to audit, indicate HPI has total assets of approximately $1,800,000, total liabilities of approximately $850,000, and net equity of approximately $950,000. For the fiscal year ended December 31, 2016, preliminary numbers, subject to audit, indicate HPI had total revenue of $Nil and total operating loss of approximately $608,000. HPI has carried forward losses of approximately $1,400,000. Newstrike is an early stage exploration company governed by the laws of Ontario, and has historically been focused on precious and base metals and other minerals exploration in Canada and the United States. Newstrike currently holds a 25% interest in the property known as the Sweetheart Property, comprised of mining claims, leases and application comprising approximately 14,000 acres, located in the vicinity of Rattlesnake Hills, Wyoming, United States. Newstrike has not undertaken any exploration on its mineral properties in the past two years. The Transaction, if completed, will constitute a "Change of Business", as defined in the policies of the TSX Venture Exchange (the "TSXV"). Trading in the common shares of Newstrike (the "Newstrike Shares") will be halted as a result of this announcement and will remain halted until the resumption of trading is approved by the TSXV. In connection with the Transaction, Newstrike proposes to complete a non-brokered private placement of up to 25,000,000 subscription receipts ("Subscription Receipts") at a price of $0.125 per Subscription Receipt to raise aggregate gross proceeds of up to $3,125,000 (the "Subscription Receipt Financing"). Each Subscription Receipt will automatically convert on the satisfaction or waiver of all conditions precedent to the Transaction and certain other ancillary conditions (the "Release Conditions") into Newstrike Shares without any further consideration on the part of the purchaser, immediately prior to effecting the Transaction. The gross proceeds from the Subscription Receipt Financing will be held in escrow pending the satisfaction of the Release Conditions, whereupon the Newstrike Shares underlying the Subscription Receipts will be issued to the purchasers and the gross proceeds of the Subscription Receipt Financing will be paid to Newstrike. In the event the Transaction does not occur by June 30, 2017, the gross proceeds of the Subscription Receipt Financing shall be returned to the purchasers pro rata without any deduction or interest and the Subscription Receipts shall be automatically cancelled. The Newstrike Shares underlying the Subscription Receipts shall be subject to a voluntary escrow period commencing on the date of issuance thereof until the later of (i) the date that is four months and a day following the closing date of the Transaction (the "Effective Date"); and (ii) such longer period as may be imposed by the applicable stock exchange, all in accordance with the terms and conditions thereof. It is anticipated that insiders of Newstrike will purchase up to 1,600,000 Subscription Receipts, and insiders of HPI will not purchase any Subscription Receipts. In connection with the Transaction, HPI also proposes to complete a non-brokered private placement (the "Debenture Financing") of unsecured, non-interest bearing convertible debentures (the "Debentures") in the aggregate principal amount of up to $1,500,000. Each $1.00 in principal amount of the Debentures shall entitle the holder thereof to acquire 1.13 common shares of HPI (each one such common share, an "Underlying HPI Share"), and shall be automatically converted into Underlying HPI Shares, without any further action or formality on the part of the holders thereof, on the earlier of (a) the date which is one year following the date of issuance of the Debentures; and (b) immediately prior to the occurrence of a Liquidity Event (as defined in the Debentures). The Transaction will constitute a Liquidity Event for the purposes of the Debentures. In the event that the outstanding principal amount of the Debentures is converted into Underlying HPI Shares immediately prior to the occurrence of a Liquidity Event, such Underlying HPI Shares shall be subject to a voluntary escrow period commencing on the date of issuance thereof until the later of (i) the date that is four months and a day following the Liquidity Event; and (ii) such longer period as may be imposed by the applicable stock exchange, all in accordance with the terms and conditions thereof. It is anticipated that no Debentures will be purchased by any insiders of Newstrike or HPI. It is intended that the net proceeds raised pursuant to the Subscription Receipt Financing and the Debenture Financing will be used for marketing initiatives, capacity expansion plans, working capital and general corporate purposes. The Transaction will be structured as a three-cornered amalgamation (the "Amalgamation") pursuant to which HPI will amalgamate with a wholly-owned subsidiary of Newstrike ("Subco") to form an amalgamated entity ("Amalco") which will continue as a wholly owned subsidiary of Newstrike. Assuming the conversion of all convertible securities of HPI other than the HPI Warrants (defined below) into common shares of HPI ("HPI Shares") prior to closing, all of the issued and outstanding HPI Shares, other than the Underlying HPI Shares, shall be exchanged for an aggregate of 269,000,000 Newstrike Shares to be distributed proportionately amongst the holders of such HPI Shares. In addition, (i) each Underlying HPI Share shall be converted into approximately 7.077 Newstrike Shares resulting in the issuance of an aggregate of up to approximately 11,996,059 Newstrike Shares; and (ii) an aggregate of up to approximately 15,994,746 Newstrike Shares shall be reserved for issuance upon exercise of the HPI Warrants (as defined below), with each such HPI Warrant entitling the holder to acquire approximately 7.077 Newstrike Shares in lieu of one HPI Share, at an exercise price of $0.125 per Newstrike Share. The deemed exchange price for the Newstrike Shares to be issued in consideration of all issued and outstanding HPI Shares shall be approximately Cdn$0.125 per share, or such other price as permitted by applicable regulatory authorities, including the TSXV. As of the date hereof, Newstrike has 46,624,581 Newstrike Shares outstanding and has issued stock options and share purchase warrants to acquire an aggregate of 21,960,000 Newstrike Shares at exercise prices ranging from $0.075 to $0.20 per share. Following the completion of the Subscription Receipt Financing, up to an additional 25,000,000 Newstrike Shares shall be issued upon conversion of the Subscription Receipts. At the time of closing of the Transaction, and assuming that the Debenture Financing is fully subscribed, it is anticipated that HPI will have approximately 1,695,000 Underlying HPI Shares and 38,008,731 additional HPI Shares outstanding, and share purchase warrants to acquire an aggregate of 2,260,000 HPI Shares at approximately $0.884 per share (the "HPI Warrants") and no other convertible securities outstanding. It is expected that following completion of the Transaction, and assuming that each of the Subscription Receipt Financing and Debenture Financing are fully subscribed, the current holders of Newstrike Shares will hold approximately 13.2% of the outstanding Newstrike Shares, the subscribers in the Subscription Receipt Financing will hold approximately 7.1% of the outstanding Newstrike Shares, and the holders of the HPI Shares (inclusive of the HPI Underlying Shares) will collectively hold approximately 79.7% of the outstanding Newstrike Shares, all as calculated on a non-diluted basis immediately following the closing of the Transaction. Upon closing of the Transaction, the board of the Newstrike shall be reconstituted to be comprised of five members, two of which shall be nominees of Newstrike and three of which shall be nominees of HPI in a manner that complies with the requirements of the TSXV and applicable securities laws. In addition, all current officers of Newstrike shall resign and be replaced by nominees of HPI. The following individuals are expected to be appointed as new directors and/or officers of Newstrike pursuant to the Transaction: AltaCorp Capital Inc. has been retained to act as sponsor in connection with the Transaction. In 2001, Jay Wilgar co-founded AIM PowerGen Corporation ("AIM"), a largescale wind power development company. In 2005, AIM was awarded a power purchase agreement with the Ontario Power Authority to build one of the largest wind power project in Canada, the Erie Shores Wind Farm. AIM was subsequently sold in 2006 to the British firm REG for $29.6 million. Since 2001, AIM and its core team have developed, built and financed over $2 billion in large scale wind power and solar power projects across Canada. Jay is 42 years old and holds a Bachelors of Commerce Degree from Wilfrid Laurier University. Peter Hwang has spent over 20 years in senior management in both the private and public sectors with extensive experience in finance, private equity, new product commercialization and customer acquisition. Peter is currently the President and CEO of Globalfaces Direct Inc. ("Globalfaces"), a direct marketing, software and data analytics company serving the largest not for profit clients in the world and acquiring over 60,000 monthly donors per year. Since the inception of Globalfaces, Peter has been responsible for the strategic direction of the organization, including finance, partnerships and corporate development. Peter is 43 years old and holds a Bachelors Degree from Wilfrid Laurier University. For over 15 years, Nik Van Haeren has worked in the family business leading multiple different projects focusing on the high scale manufacturing and development of efficient lighting systems. Nik is currently the President of Enerworks Solar Heating ("Enerworks") and Cooling and Uvalux Tanning & Support ("Uvalux"). Enerworks is a manufacture of Solar Heating Equipment and provides commercial heating and cooling solutions for a wide range of industries focusing on the development of green technologies to preserve energy for large scale commercial applications. Uvalux is Canada's largest supplier to the Salon industry across the country with over 2500 retailers across Canada and was voted one of Canada's Top 50 Employers. Nik is 37 years old and holds a Bachelors Degree from Western University and is a graduate from the Entrepreneurial Masters Program at MIT. It is anticipated that immediately following the Transaction, the only shareholder that will hold greater than 10% of the issued and outstanding Newstrike Shares will be 2497895 Ontario Inc. ("2497895"), a company governed by the laws of Ontario. Assuming that each of the Debenture Financing and Subscription Receipt Financing are fully subscribed, it is anticipated that 2497895 will hold approximately 104,278,985 Newstrike Shares, representing approximately 29.57% of all issued and outstanding Newstrike Shares immediately following the completion of the Transaction. The directors and officers of 2497895 Ontario Inc. consist of Nik Van Haeren and Jeff Van Haeren. Jeff Van Haeren is the President of Trigon Construction Management ("Trigon"), which has offices in Calgary, Toronto, Ottawa, Halifax and Woodstock. Trigon employs over 80 construction professionals providing construction services in the industrial, commercial and institutional sectors. Some of Trigon's recent clients include Deloitte, Slaight Communications, Ole Media, NWMO, DRI Capital, SAB Miller, Magna, and Octa Pharma. Additionally, Jeff functions as the Director of Construction for Goodlife Fitness where he oversees capital budgets, club design, and construction, as well as being involved in company strategy, site selection, facility maintenance, leasing and acquisitions. Jeff is 35 years old and attended The University of Western Ontario. Completion of the Transaction is subject to a number of conditions, including, but not limited to, TSXV acceptance and shareholder approval of HPI. Newstrike will not be required to obtain shareholder approval of the Transaction pursuant to Section 4.1 of TSXV Policy 5.2 as a result of the following factors: (i) the Transaction is not a "related party transaction" (within the meaning of TSXV policies); (ii) Newstrike is without active operations; (iii) Newstrike is not and will not be subject to a cease trade order or suspended from trading upon completion of the Transaction; and (iv) Newstrike shareholder approval of the Transaction is not required to be obtained under applicable corporate or securities laws. Where applicable, the Transaction cannot close until the required shareholder and regulatory approvals are obtained. There can be no assurance that the Transaction will be completed as proposed, or at all. Other conditions to completion of the Transaction include, but are not limited to: Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable, shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all. Further details about the proposed Transaction will be provided in the disclosure document to be prepared and filed in respect of the Transaction. Investors are cautioned that, except as disclosed in the disclosure document to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Newstrike should be considered highly speculative. The TSXV has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release. This press release contains forward-looking information based on current expectations. Statements about the closing of the Transaction, the Subscription Receipt Financing and the Debenture Financing, expected terms of the Transaction and such financings, the number of securities that may be issued in connection with the Transactions and such financings and the parties' ability to satisfy closing conditions and receive necessary approvals are all forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Transaction, the Subscription Receipt Financing or the Debenture Financing will occur or that, if the Transaction and/or any such financing does occur, it will be completed on the terms described above. Newstrike assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
News Article | February 28, 2017
TORONTO, ONTARIO--(Marketwired - Feb. 28, 2017) - The Executive Council of the Canadian Bankers Association (CBA) today announced the appointment of Neil Parmenter as President and Chief Executive Officer of the CBA, effective May 1, 2017. Mr. Parmenter succeeds Terry Campbell, who announced his retirement in September 2016 and has been in this role for six years. "We are pleased to have Neil lead the CBA and are confident his extensive knowledge of banking and hands on experience in government relations will ensure he is an effective voice for the industry," said Mr. Cameron Fowler, Group Head, Canadian Personal & Commercial Banking at Bank of Montreal and Chair of the CBA's Executive Council. "We would also like to thank Terry for his exceptional work as CBA President and throughout his 20 years at the CBA. He provided strong leadership on behalf of the industry, particularly following the global financial crisis, and strengthened the reputation of banks in Canada. We wish Terry all the best in his retirement." Mr. Parmenter is currently the Senior Vice President, Corporate and Public Affairs (Global) and Chief Communications Officer at TD Bank Group. He leads TD's Corporate Communications for Canada and the United States and he leads TD's Canadian Government Relations practice, and counsels the CEO, CFO, Senior Executive Team and Board of Directors on key government relations, communications, and public affairs issues. He also sits on TD's Enterprise Reputational Risk Committee and Senior Executive Crisis Communications team. "We have a very competitive and strong banking sector that plays a significant role in the Canadian economy and helps Canadians achieve their financial goals," said Neil Parmenter. "I am honoured to be taking on this leadership role at the CBA where I will be representing such a key national industry." Neil holds a B.A. in Political Science from Western University, a Certificate in Public Relations from Humber College, a Canadian Securities designation and completed an Executive Program in Strategic Marketing Management from Stanford University. He has won several industry awards from the Canadian Public Relations Society (CPRS) and the International Association of Business Communicators (IABC). He also serves as a Director of the Toronto Financial Services Alliance and the Institute for Public Relations. The Canadian Bankers Association works on behalf of 61 domestic banks, foreign bank subsidiaries and foreign bank branches operating in Canada and their 280,000 employees. The CBA advocates for effective public policies that contribute to a sound, successful banking system that benefits Canadians and Canada's economy. The Association also promotes financial literacy to help Canadians make informed financial decisions and works with banks and law enforcement to help protect customers against financial crime and promote fraud awareness. www.cba.ca
News Article | February 23, 2017
BEVERLY HILLS, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (TOMI) (OTCQX:TOMZ), a global bacteria decontamination and infection prevention company, and its board of directors announced the formation and approval of TOMI’s scientific advisory board. “We are honored William, Miguel and Helene – experts in intellectual property law, biosafety and infection prevention, respectively – have agreed to join our scientific advisory board,” stated Dr. Halden Shane, TOMI’s Chief Executive Officer. “We believe their support validates TOMI’s groundbreaking SteraMist™, and their guidance will help TOMI in "Innovating for a Safer World.” The team is charged with constructively challenging management to help develop strategy; ensuring the necessary resources are in place to enable us to achieve objectives in scientific research and development; and monitoring technological and regulatory trends that could impact our business as well as our performance against our goals. We believe their insight will be invaluable.” William M. Brown, PhD, MBA, JD William M. Brown, PhD, MBA, JD is a consultant and advisor to a series of biotech and life sciences companies. Dr. Brown is a seasoned attorney in intellectual property with deep experience in healthcare-related matters. He is licensed to practice law in several states and is a registered patent attorney. His consulting experience includes intellectual property portfolio management, clinical trial contracts, and patent/business development matters. He holds a PhD from the University of Southampton, England, an MBA from Fairleigh Dickinson University, and a JD from New York Law School. Dr. Brown conducted postdoctoral research at Harvard, Johnson & Johnson, NIH, and Memorial Sloan-Kettering Cancer Center. Miguel A. Grimaldo, MEng Miguel A. Grimaldo, MEng is an Assistant Professor for the Department of Pathology, Director of Institutional Biocontainment Resources at the University of Texas Medical Branch (UTMB) and the Director of the Biocontainment Engineering Division for the Galveston National Laboratory. His responsibilities include the review of all design, construction, commissioning and operation of High and Maximum containment laboratories as well as to ensure regulatory compliance and to conduct ongoing evaluation and recertification on all critical containment features, equipment and operations for Biosafety Level 3 (BSL‐3), Animal Biosafety Level 3 (ABSL3) and Biosafety Level 4 (BSL4) laboratory facilities at UTMB. He is also a member of the UTMB Institutional Biosafety Committee. He has served as Committee Member for development of the ANSI Z9.14‐2014 Standard ‐ Testing and Performance‐Verification Methodologies for Ventilation Systems for Biosafety Level 3 (BSL‐3) and Animal Biosafety Level 3 (ABSL‐3) facilities as well as for the 2016 Edition of the National Institute of Health (NIH) ‐ Design Requirements Manual (DRM) for Biomedical Laboratories and Animal Research Facilities. Miguel routinely serves as Biocontainment Advisor for containment laboratories nationally and internationally on design, construction and operations and also routinely contributes to a technical column in the American Biological Safety Association (ABSA) journal, Applied Biosafety entitled, “Containment Talk”. Mr. Grimaldo obtained his Masters of Engineering from the University of Louisville and Bachelor of Science degrees in Agricultural Engineering and Agricultural Economics from Texas A&M University. Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC, is an Infection Preventionist, owner of Bio Guidance, LLC, adjunct biology professor at Rowan University and Director of Infection Prevention at Saint Francis Healthcare. She is Infection Control Certified (CIC), board certified as an International Medical Laboratory Scientist and holds a PhD in Epidemiology. Dr. Paxton has 40 plus years’ experience in medical devices and infectious disease consulting. Dr. Paxton obtained her PhD from Kennedy Western University and her MS from Bowling Green State University. Scientific Advisory Board Provisions and criteria have been set in the company's bylaws and scientific advisory board charter. TOMI’s scientific advisory board will always observe in the letter and spirit the duties, rights and role as a member of the company's board as stipulated in the relevant listing standards. About TOMI™ Environmental Solutions, Inc. TOMI™ Environmental Solutions, Inc. (OTCQX:TOMZ) is a global bacteria decontamination and infectious disease control company, providing eco-friendly environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier platform of Hydrogen Peroxide based product that uses Binary Ionization Technology® (BIT™) , a state of the art technology for the production of its Activated Ionized Hydrogen Peroxide mist represented by the TOMI™ SteraMist™ brand. TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences. TOMI also develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association. For additional product information, visit www.tomimist.com or contact us at email@example.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
News Article | February 27, 2017
NORWALK, Connecticut, 27 febbraio 2017 /PRNewswire/ -- Mederi Therapeutics ha annunciato oggi la pubblicazione di una meta analisi di 28 studi, che rappresentano 2468 pazienti sottoposti alla Terapia Stretta per il trattamento della malattia da reflusso gastroesofageo (MRGE). Lo studio dal titolo "Systematic Review and Meta-Analysis of Controlled and Prospective Cohort Efficacy Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal Reflux Disease (Riesame sistematico e meta analisi degli studi controllati e prospettici dell'efficacia per coorti della radiofrequenza endoscopica per il trattamento della malattia da reflusso gastroesofageo" è stato pubblicato in Surgical Endoscopy. Tra gli autori ci sono Ronnie Fass, MD, responsabile dello Esophageal and Swallowing Center (Centro esofageo e per la deglutizione), Director of Gastroenterology and Hepatology (Direttore di gastroenterologia ed epatologia) presso il Metro Health Medical Center e Professore presso la Case Western University, e l'esperto di statistica Frederick Cahn, PhD, direttore di Strategie Biomediche. L'autore principale, il dott. Ronnie Fass ha commentato, "Questa analisi completa ha combinato la nostra esperienza clinica con l'esperienza statistica del dott. Cahn per produrre il riesame più completo e oggettivo dei dati disponibili al momento. I risultati hanno dimostrato che Stretta è una terapia clinicamente efficace e sicura per la MRGE." Il dott. Cahn, che vanta oltre 30 anni di esperienza nel settore sanitario, ha sottolineato gli standard elevati del presente studio. "L'analisi completa degli studi, sulla base della metodologia consigliata da Cochrane, ha dimostrato che sono di qualità elevata con un basso rischio di distorsione. Abbiamo anche rilevato una elevata quantità di risultati positivi nell'ampio numero di studi. I punti di forza di questa meta analisi comprendono: follow-up fino a 10 anni (25 mesi in media), un gran numero di soggetti (2468), e l'inclusione di 28 studi, dati che collocano questa meta analisi nell'1% dei riesami e delle meta analisi sistematiche di alto livello." Il dott. Fass ha spiegato, "I risultati di questo studio evidenziano che Stretta riduce in modo significativo i sintomi della MRGE, e al tempo stesso si riflette sui parametri fisiologici, quali ad esempio la riduzione dell'esposizione agli acidi, e la guarigione delle esofagiti erosive." La malattia da reflusso gastroesofageo (MRGE) è la condizione in cui si ha il reflusso del contenuto dello stomaco nell'esofago con sintomi quali il bruciore di stomaco e il rigurgito. Questo reflusso si verifica a causa della debolezza della barriera muscolare tra lo stomaco e l'esofago. La cura più comune della MRGE è rappresentata da cure mediche, di solito inibitori della pompa protonica, tuttavia. il 30 percento circa dei pazienti non ha un sollievo sufficiente da queste cure mediche, e altri sono preoccupati dai rischi associati a lungo termine. Stretta applica livelli bassi di energia in radiofrequenza (RF) al muscolo dello sfintere esofageo inferiore. Il trattamento ispessisce il muscolo dello sfintere, riducendo la cedevolezza del tessuto e il rilassamento transiente del muscolo dello sfintere esofageo inferiore, migliorando la barriera tra lo stomaco e l'esofago e migliorando i sintomi della MRGE. Stretta è un trattamento non chirurgico endoscopico che offre un'alternativa notevolmente più sicura e meno invasiva rispetto a quella di interventi chirurgici anti reflusso, e inoltre libera da cure mediche a cui sottoporsi per tutta la vita. I dati economici sulla salute, pubblicati di recente, dimostrano che il trattamento della MRGE con Stretta ha portato a importanti risparmi nei costi per gli utenti soggetti al pagamento, rispetto alle cure mediche a lungo termine o agli interventi chirurgici. "La combinazione della nostra nuova meta analisi e dei dati economici fornisce ulteriore supporto all'uso di Stretta come trattamento per i pazienti affetti da MRGE," ha aggiunto Fass. Bob Knarr, Amministratore Delegato di Mederi ha spiegato l'impatto di questo studio. "Questa approfondita analisi dati conferma che Stretta è sicuro ed efficace nel trattamento della MRGE. Questo nuovo studio combinato con i dati economici fanno di Stretta una scelta vincente per i pazienti e per gli utenti soggetti al pagamento, migliorando la qualità delle cure e riducendo i costi al tempo stesso."
Etude historique la meta analyse de 28 etudes montre que la therapie Stretta utilisee dans le traitement du reflux gastro oesophagien ameliore systematiquement et sensiblement la condition des patients
News Article | February 27, 2017
NORWALK, Connecticut, 27 février 2017 /PRNewswire/ -- Mederi Therapeutics a annoncé aujourd'hui la publication d'une méta-analyse de 28 études, représentant 2 468 patients qui ont bénéficié de la thérapie Stretta dans le traitement du reflux gastro-œsophagien (GERD). Cette étude, intitulée « Systematic Review and Meta-Analysis of Controlled and Prospective Cohort Efficacy Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal Reflux Disease », a été publiée dans la revue Surgical Endoscopy. Parmi ses auteurs figurent le docteur Ronnie Fass, MD, chef du centre de l'œsophage et de la déglutition, directeur de gastro-entérologie et d'hépatologie au Metro Health Medical Center et professeur à la Case Western University, et l'expert en statistiques Frederick Cahn, PhD, principal de Biomedical Strategies. Pour l'auteur en chef, le docteur Ronnie Fass : « Cette analyse exhaustive a fait intervenir notre savoir-faire clinique et mobilisé en même temps l'expérience en statistiques du docteur Cahn afin de réaliser l'examen le plus approfondi et le plus objectif des données actuellement disponibles. Les résultats montrent que Stretta constitue une thérapie cliniquement efficace et sûre dans le traitement du GERD ». Le Dr Cahn, qui a à son actif plus de 30 années d'expérience des soins de santé, a relevé le niveau très élevé de cette étude. « Une analyse approfondie des études, en faisant appel à la méthodologie recommandée par Cochrane, a démontré qu'elles étaient d'une grande qualité et présentaient un faible risque d'erreur systématique. Nous avons également constaté une convergence des résultats positifs sur l'ensemble des études. Parmi les atouts de cette méta-analyse figurent : jusqu'à 10 années de suivi (moyenne de 25 mois), un nombre élevé de sujets (2 468) et l'inclusion de 28 études, ce qui place cette méta-analyse dans le 1 % de tête des examens systématiques et des méta-analyses ». Pour le Dr Fass : « Les résultats de cette étude montrent que Stretta atténue sensiblement les symptômes du GERD tout en impactant les paramètres physiologiques, comme la réduction de l'exposition à l'acide et la guérison de l'œsophagite ulcérative ». Le reflux gastro-œsophagien (GERD) est une affection dans laquelle le contenu de l'estomac repasse dans l'œsophage, ce qui engendre des symptômes comme des brûlures d'estomac et de la régurgitation. Ce reflux survient en raison d'une faiblesse du muscle qui sépare l'estomac de l'oesophage. Le traitement du GERD fait le plus souvent appel à des médicaments, habituellement des PPI, mais environ 30 pour cent des patients ne sont pas soulagés avec ces médicaments, tandis que d'autres s'inquiètent de leurs effets à long terme. Stretta applique une faible quantité d'énergie de radiofréquence (RF) sur le muscle du sphincter œsophagien inférieur (LES). Ce traitement permet d'épaissir le muscle du sphincter, ce qui réduit l'élasticité des tissus et les relâchements passagers du LES, renforçant ainsi la barrière entre l'estomac et l'oesophage, et atténuant les symptômes du GERD. Stretta est un traitement endoscopique non chirurgical qui offre une solution nettement plus sûre et moins invasive en remplacement d'une chirurgie anti-reflux et qui évite aux personnes concernées de prendre des médicaments tout au long de leur vie. Des données économiques sur la santé récemment publiées montrent que traiter le GERD avec Stretta permet aux établissements payeurs de réaliser d'importantes économies de coûts par rapport à une médication de longue durée ou à une chirurgie. « La combinaison de notre nouvelle méta-analyse et des données économiques milite encore davantage en faveur de l'emploi de Stretta dans le traitement des patients atteints de GERD », ajoute Fass. Bob Knarr, PDG de Mederi, a expliqué l'impact de cette étude : « Cette analyse de données en profondeur confirme que Stretta est sûr et efficace dans le traitement du GERD. Cette nouvelle étude, en plus des données économiques, font de Stretta une solution idéale tant pour les patients que pour les organismes payeurs, améliorant la qualité de vie tout en réduisant les coûts ». A PROPOS DE MEDERI® ET DE STRETTA® Mederi fabrique des dispositifs médicaux innovants qui font appel à l'énergie RF non ablative pour traiter les maladies digestives. Au terme de plus de 40 études avec un suivi à long terme jusqu'à 10 ans, il a été démontré que Stretta était sûr et efficace dans le traitement du GERD. Stretta est disponible dans le monde entier. Mederi a fourni son appui pour l'analyse statistique de cette étude. Pour de plus amples informations, rendez-vous sur stretta-therapy.com ou formez le +1-855-855-3639.
News Article | February 27, 2017
NORWALK, Connecticut, Feb. 27, 2017 /PRNewswire/ -- Mederi Therapeutics today announced the publication of a meta-analysis of 28 studies, representing 2468 patients who received Stretta Therapy to treat gastroesophageal reflux disease (GERD). The study entitled, "Systematic Review and Meta-Analysis of Controlled and Prospective Cohort Efficacy Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal Reflux Disease", was published in Surgical Endoscopy. Authors included Ronnie Fass, MD, head of the Esophageal and Swallowing Center, Director of Gastroenterology and Hepatology at Metro Health Medical Center and Professor at Case Western University, and statistical expert Frederick Cahn, PhD, principal of Biomedical Strategies. Lead author Dr. Ronnie Fass noted, "This comprehensive analysis combined our clinical expertise with Dr. Cahn's statistical experience to produce the most thorough and objective review of currently available data. The results demonstrate that Stretta is a clinically effective and safe therapy for GERD." Dr. Cahn, who has more than 30 years of healthcare experience, noted the high standards of this study. "A thorough analysis of the studies, following Cochrane recommended methodology, demonstrated they are of a high quality with low risk of bias. We also noted a consistency of positive outcomes across the wide range of studies. Strengths of this meta-analysis include: up to 10-years of follow-up (average 25 months), a large number of subjects (2468), and the inclusion of 28 studies, which places this meta-analysis in the top 1% of systematic reviews and meta-analyses." Dr. Fass explained, "The results of this study show that Stretta significantly reduces GERD symptoms while also impacting the physiological parameters, such as reducing acid exposure, and healing erosive esophagitis." Gastroesophageal Reflux Disease (GERD) is a condition where stomach contents reflux up into the esophagus causing symptoms like heartburn and regurgitation. This reflux occurs due to a weakness in the barrier muscle between the stomach and esophagus. The most common GERD treatment is medications, usually PPIs, however, about 30 percent of patients do not get adequate relief from these medications, and others are concerned about associated long-term risks. Stretta applies low levels of radiofrequency (RF) energy to the lower esophageal sphincter (LES) muscle. The treatment thickens the sphincter muscle, reducing tissue compliance and transient relaxations of the LES, improving the barrier between the stomach and esophagus, and improving GERD symptoms. Stretta is a non-surgical, endoscopic treatment that offers a significantly safer and less invasive alternative to anti-reflux surgery and freedom from life-long medication. Recently published health economic data demonstrate that treating GERD with Stretta results in significant cost savings to payers, compared to long-term medications or surgery. "The combination of our new meta-analysis and the economic data further support the use of Stretta as a treatment for GERD patients," Fass added. Bob Knarr, CEO of Mederi explained the impact of this study. "This in-depth data analysis confirms that Stretta is safe and effective in treating GERD. This new study together with the economic data make Stretta a win for patients and payers alike, improving quality of care while reducing costs." Mederi manufactures innovative medical devices that use non-ablative RF energy to treat digestive diseases. Stretta has been proven safe and effective for GERD in more than 40 studies with long-term follow up of 10-years. Stretta is available worldwide. Mederi provided support for the statistical analysis for this study. For more information: stretta-therapy.com, or call +1-855-855-3639.
News Article | February 27, 2017
NORWALK, Connecticut, 27. Februar 2017 /PRNewswire/ -- Mederi Therapeutics gab heute die Veröffentlichung einer Metaanalyse von 28 Studien bekannt, in denen 2.468 Patienten mit der Stretta Therapie für gastroesophageale Rückfluss-Krankheit (GERD) behandelt wurden. Die Studie mit dem Titel „Systematic Review and Meta-Analysis of Controlled and Prospective Cohort Efficacy Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal Reflux Disease" [Systematische Überprüfung und Metanalyse von kontrollieren und prospektiven Wirksamkeitsstudien über die Behandlung mit endoskopischer Hochfrequenz von Kohorten mit gastroesophagealer Rückfluss-Krankheit] wurde in Surgical Endoscopy veröffentlicht. Zu den Autoren zählen Dr. Ronnie Fass, Head of the Esophageal and Swallowing Center, Director of Gastroenterology and Hepatology am Metro Health Medical Center und Professor an der Case Western University, sowie der Statistikexperte, Dr. Frederick Cahn, Inhaber von Biomedical Strategies. Der Hauptautor, Dr. Ronnie Fass, erklärte: „Diese umfassende Analyse kombinierte unser klinisches Fachwissen mit der Statistikerfahrung von Dr. Cahn und lieferte die bisher gründlichste und objektivste Untersuchung der verfügbaren Daten. Die Ergebnisse zeigen, dass Stretta eine klinisch wirksame und sichere Therapie für GERD ist." Dr. Cahn, der über mehr als 30 Jahre Erfahrung im Gesundheitswesen verfügt, wies auf den hohen Standard dieser Studie hin. „Eine gründliche Analyse dieser Studien nach der von Cochrane empfohlenen Methode zeigte, dass sie von hoher Qualität sind und geringes Verzerrungspotenzial besitzen. Des Weiteren stellten wir konsistent positive Ergebnisse im gesamten Studienspektrum fest. Zu den Stärken dieser Metaanalyse zählen: bis zu 10 Jahre Nachkontrollen (Durchschnitt 25 Monate), eine große Anzahl von Probanden (2.468) und die Erfassung von 28 Studien, womit diese Metaanalyse zu den Top 1 % von systematischen Überprüfungen und Metaanalysen zählt." Dr. Fass erklärte: „Die Ergebnisse dieser Studie zeigen, dass Stretta die GERD-Symptome erheblich reduziert und gleichzeitig Auswirkungen auf physiologische Parameter hat, wie z. B. die Säureeinwirkung und die Heilung von erosiver Ösophagitis." Die gastroesophageale Rückfluss-Krankheit (GERD) ist ein Zustand, bei dem der Mageninhalt bis in die Speiseröhre zurückfließt und zu Symptomen wie Sodbrennen und Regurgitation führt. Dieser Reflux entsteht aufgrund einer Schwäche der Muskelbarriere zwischen dem Magen und der Speiseröhre. GERD wird zumeist mit Arzneimitteln behandelt, üblicherweise mit PPIs. Allerdings wirken diese Arzneimittel bei ca. 30 Prozent der Patienten nur unzureichend und andere sind über die damit verbundenen Langzeitrisiken besorgt. Stretta wendet geringe Niveaus von Hochfrequenzenergie (HF) auf den unteren Ösophagussphinkter (UÖS) an. Die Behandlung verdickt den Schließmuskel, reduziert die Gewebeweichheit und transiente Relaxationen des UÖS, stärkt die Barriere zwischen dem Magen und der Speiseröhre und lindert die GERD-Symptome. Stretta ist eine nicht chirurgische Behandlung, die eine nennenswert sicherere und weniger invasive Alternative zu Antireflux-Operationen und Abhängigkeit von Arzneimitteln bietet. Unlängst veröffentlichte gesundheitsökonomische Daten zeigen, dass die Behandlung von GERD mit Stretta im Vergleich zu langfristiger medikamentöser oder operativer Behandlung zu nennenswerten Kosteneinsparungen für Zahler führt. „Die Kombination unserer neuen Metaanalyse und der wirtschaftlichen Daten unterstützt erneut die Verwendung von Stretta als Behandlungsmöglichkeit von GERD-Patienten", fügte Fass hinzu. Bob Knarr, CEO von Mederi, erklärte die Auswirkungen dieser Studie. „Diese ausführliche Analyse bestätigt, dass Stretta bei der Behandlung von GERD sicher und wirksam ist. Diese neue Studie und die wirtschaftlichen Daten zeigen, dass Stretta sowohl Patienten als auch Zahlern klare Vorteile durch die Verbesserung der Pflegequalität bei gleichzeitiger Kostenreduzierung bietet." Mederi stellt innovative medizinische Geräte her, die nicht-ablative HF-Energie zur Behandlung von Erkrankungen des Verdauungsapparates verwenden. Stretta wurde in über 40 Studien mit langfristigen Kontrollen über 10 Jahre als sicher und effektiv bei GERD betätigt. Stretta ist weltweit erhältlich. Mederi hat die statistische Analyse dieser Studie unterstützt. Weiterführende Informationen finden Sie unter: stretta-therapy.com, oder rufen Sie +1-855-855-3639 an.
News Article | February 15, 2017
Western University of Health Sciences’ Board of Trustees has named FamilyCare Health co-founder Jeff Heatherington as its newest member. Portland, Oregon-based FamilyCare Health is a Medicare and Medicaid managed care organization providing health plan services to approximately 125,000 members. Heatherington, who is president and CEO of FamilyCare Health, has a history with WesternU’s College of Osteopathic Medicine of the Pacific (COMP) that dates to its founding in 1977. While serving as director of the Osteopathic Physicians and Surgeons of Oregon, Heatherington helped bring together Western University of Health Sciences and Samaritan Health Services to build the COMP-Northwest campus in Lebanon, Oregon. “As our presence in the Northwest continues to grow, we felt a need to get representation from the Oregon area,” said WesternU Board of Trustees Chairman Richard Bond, DO, DrPH. “We felt that Mr. Heatherington would be a good fit for our board because of his long-term presence in the Northwest. He will bring a fresh business perspective in our efforts to include the Northwest on our board.” FamilyCare Health is the only osteopathic HMO in the United States, and osteopathic medicine has been a key element of its philosophy of care since its inception. Heatherington’s father, J. Scott Heatherington, DO, was a central figure in Oregon’s osteopathic medical profession. “Osteopathic medicine has been important to me both personally and professionally,” Heatherington said. “I’m honored to join the Board and I look forward to supporting the university and future generations of medical providers.” Western University of Health Sciences (http://www.westernu.edu), located in Pomona, Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biomedical sciences, dental medicine, health sciences, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician assistant studies, podiatric medicine and veterinary medicine. WesternU is home to the Patient Care Center, where the best in collaborative health care services is offered. The Chronicle of Higher Education named WesternU a Great College to Work For in 2012, 2013, 2014, 2015 and 2016.